The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ulanova A.A.

Russian University of Medicine, Moscow, Russia

Tlevasov I.Z.

Russian University of Medicine, Moscow, Russia

Lapik D.D.

Independent Researcher, Krasnodar, Russia

Sharaeva N.D.

Saint Petersburg State Pediatric Medical University, St. Petersburg, Russia

Tekueva Z.Z.

Saint Petersburg State Pediatric Medical University, St. Petersburg, Russia

Strategies for the treatment of gout: control of hyperuricemia and prevention of complications

Authors:

Ulanova A.A., Tlevasov I.Z., Lapik D.D., Sharaeva N.D., Tekueva Z.Z.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2026;29(3): 109‑115

DOI: 10.17116/profmed202629031109

Read: 512 times

Contact the author
Table of contents

STRATEGIES FOR THE TREATMENT OF GOUT: CONTROL OF HYPERURICEMIA AND PREVENTION OF COMPLICATIONS
STRATEGIES FOR THE TREATMENT OF GOUT: CONTROL OF HYPERURICEMIA AND PREVENTION OF COMPLICATIONS

To cite this article:

Ulanova AA, Tlevasov IZ, Lapik DD, Sharaeva ND, Tekueva ZZ. Strategies for the treatment of gout: control of hyperuricemia and prevention of complications. Russian Journal of Preventive Medicine. 2026;29(3):109‑115. (In Russ.)
https://doi.org/10.17116/profmed202629031109

 
Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Hype­ruricemia as therapeutic target in the meta­bolic dysfunction-associated steatotic liver disease. Russian Journal of Preventive Medi­cine. 2025;(10):93-98
Gut ecosystem: a new insi­ght on hype­ruricemia mechanisms. Russian Journal of Preventive Medi­cine. 2026;(1):123-129
Hype­ruricemia in patients with the chro­nic obstructive pulmonary disease exacerbation. Russian Journal of Preventive Medi­cine. 2026;(5):32-38
Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14
Mechanism of action of various therapies for viti­ligo. Pharmacologist’s and dermatovenerologist’s perspective. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(6):734-741
Ecto­pic pregnancy in the inte­rstitial fallopian tube. Russian Bulletin of Obstetrician-Gynecologist. 2026;(3):55-59
Abstract:

Gout is a metabolic disease characterized by chronic hyperuricemia and the deposition of sodium monourate crystals in tissues. With the increasing prevalence of the disease, there is a need to change therapeutic strategies.

OBJECTIVE

To analyze current data on strategies for treatment and prevention of gout and its complications.

MATERIALS AND METHODS

The review was based on an analysis of papers published in international and Russian scientific databases (PubMed, Scopus, Web of Science, eLibrary) for 2019—2025. Original studies, meta-analyses, and reviews that meet the criteria of scientific reliability, clinical significance, and relevance were included. The publications were selected using keywords in Russian and English, in accordance with the guidelines of leading international and national professional communities.

RESULTS

Data from clinical studies confirming the efficacy of uricostatic agents with appropriate dose titration are presented. Benzbromarone was found to have high urate-lowering activity in patients with hypouricosuric hyperuricemia. Particular attention is paid to promising selective inhibitors of uric acid transporter proteins that provide clinical efficacy and an acceptable safety profile. The potential of enzyme-based agents, in particular pegloticase, whose effectiveness increases significantly when combined with methotrexate, was analyzed.

CONCLUSION

Current strategies for the treatment of gout focus on achieving a sustained reduction in uric acid levels to target values, while accounting for the pathogenetic mechanisms of hyperuricemia. Individualized drug selection improves treatment efficacy. New selective drugs and combinations of biological agents with immunosuppressants offer prospects for treating resistant forms of gout.

Keywords:

gout
hyperuricemia
urate-lowering therapy
uricosuric drugs
uricostatics
pegloticase
dotinurad
methotrexate

Authors:

Ulanova A.A.

Russian University of Medicine, Moscow, Russia

Tlevasov I.Z.

Russian University of Medicine, Moscow, Russia

Lapik D.D.

Independent Researcher, Krasnodar, Russia

Sharaeva N.D.

Saint Petersburg State Pediatric Medical University, St. Petersburg, Russia

Tekueva Z.Z.

Saint Petersburg State Pediatric Medical University, St. Petersburg, Russia

Received:

15.11.2025

Accepted:

24.11.2025

Close metadata

References:

  1. Eliseev MS, Nasonov EL. Treatment and diagnostics of gout: Unsolved problems in clinical practice. Nauchno-prakticheskaja revmatologija. 2024; 62(1):7-12. (In Russ.). https://doi.org/10.47360/1995-4484-2024-7-12
  2. Li Y, Chen Z, Xu B et al. Global, regional, and national burden of gout in elderly 1990-2021: an analysis for the global burden of disease study 2021. BMC Public Health. 2024;(24):3298. https://doi.org/10.1186/s12889-024-20799
  3. GBD 2021 Gout Collaborators. Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatology. 2024;6(8):e507-e517. https://doi.org/10.1016/S2665-9913(24)00117-6
  4. Yang Y, Liu Z. The changing burden of gout in adults aged 70 and above based on the Global Burden of Disease 2019. Frontiers in Public Health. 2025;(13):1455726. https://doi.org/10.3389/fpubh.2025.1455726
  5. Asghari KM, Zahmatyar M, Seyedi F et al. Gout: global epidemiology, risk factors, comorbidities and complications: a narrative review. BMC Musculoskeletal Disorders. 2024;25(1):1047. https://doi.org/10.1186/s12891-024-08180-9
  6. Smolen JS, Landewé RBM, Bergstra SA et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023; 82(1):3-18.  https://doi.org/10.1136/ard-2022-223356
  7. Fraenkel L, Bathon JM, England BR et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-939.  https://doi.org/10.1002/acr.24596
  8. Panina EV. Mechanisms of cartilage damage in gout and hyperuricemia. Nauchno-prakticheskaja revmatologija. 2024;62(2):162-167. (In Russ.). https://doi.org/10.47360/1995-4484-2024-162-167
  9. Cheremushkina EV, Eliseev MS. Hyperuricemia and gout: effects on bone and articular cartilage (literature review). Ozhirenie i metabolizm. 2022;19(3): 348-357. (In Russ.). https://doi.org/10.14341/omet12894
  10. Drapkina OM, Mazurov VI, Martynov AI et al. «Focus on hyperuricemia». The resolution of the Expert Council. Kardiovaskuljarnaja terapija i profilaktika. 2023;22(4):3564. (In Russ.). https://doi.org/10.15829/1728-8800-2023-3564
  11. Eliseeva ME, Eliseev MS. The Importance of Hyperuricemia in the Development of Human Diseases and Methods of Its Correction. Doctor.Ru. 2019;2(157):47-54. (In Russ.). https://doi.org/10.31550/1727-2378-2019-157-2-47-54
  12. Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. American Journal of Translational Research. 2020;12(7):3167-3181.
  13. Danve A, Sehra ST, Neogi T. Role of diet in hyperuricemia and gout. Best Practice and Research. Clinical Rheumatology. 2021;35(4):101723. https://doi.org/10.1016/j.berh.2021.101723
  14. Li R, Wu B, Han M et al. Uric acid metabolic disorders in pituitary-target gland axis. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2024;(17):661-673.  https://doi.org/10.2147/DMSO.S448547
  15. Parisa N, Kamaluddin MT, Saleh MI, Sinaga E. The inflammation process of gout arthritis and its treatment. Journal of Advanced Pharmaceutical Technology and Research. 2023;14(3):166-170.  https://doi.org/10.4103/japtr.japtr_144_23
  16. Sanchez C, Campeau A, Liu-Bryan R et al. Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators. Scientific Reports. 2024;(14):24598. https://doi.org/10.1038/s41598-024-24598-5
  17. O’Dell JR, Brophy MT, Pillinger MH et al. Comparative effectiveness of allopurinol and febuxostat in gout management. New England Journal of Medicine. 2022;1(3):10.1056/evidoa2100028. https://doi.org/10.1056/EVIDoa2100028
  18. Kaufmann D, Chaiyakunapruk N, Schlesinger N. Optimizing gout treatment: A comprehensive review of current and emerging uricosurics. Joint Bone Spine. 2025;92(2):105826. https://doi.org/10.1016/j.jbspin.2024.105826
  19. Yan F, Xue X, Lu J et al. Superiority of low-dose benzbromarone to low-dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion. Arthritis and Rheumatology. 2022;74(12):2015-2023. https://doi.org/10.1002/art.42266
  20. Keenan RT, Shen Z, Yan S et al. How URAT1 inhibitors can shape the future of chronic gout treatment: a narrative review of uricosurics past and present. Exploration of Musculoskeletal Diseases. 2024;(2):529-554.  https://doi.org/10.37349/emd.2024.00077
  21. Hosoya T, Sano T, Sasaki T et al. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study. Clinical and Experimental Nephrology. 2020;24(1):53-61.  https://doi.org/10.1007/s10157-019-01818-2
  22. Peng X, Li X, Xie B et al. Gout therapeutics and drug delivery. Journal of Controlled Release. 2023;(362):728-754.  https://doi.org/10.1016/j.jconrel.2023.08.019
  23. Botson JK, Saag K, Peterson J et al. A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. Arthritis and Rheumatology. 2023;75(2):293-304.  https://doi.org/10.1002/art.42335
  24. Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397(10287):1843-1855. https://doi.org/10.1016/S0140-6736(21)00569-9
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.